Clinical Trials Logo

Clinical Trial Summary

A 12-week clinical study to evaluate the safety and efficacy of T92 in pediatric patients with Tourette Syndrome.

Clinical Trial Description

This is a multi-center, randomized, double-blind, placebo-controlled, outpatient clinical study designed to evaluate the efficacy and safety of T92 in Tourette Syndrome pediatric patients. This trial consists of a screening/wash-out period of up to 6 weeks, an 8-week supportive care period and a 4-week follow-up period for all subjects who completed the study. For the first two weeks, the patients will continue to take T92 at half dose and the T92 administration will be stopped from week 3 of the follow-up period. Subjects will be randomly assigned to receive T92 or matching placebo based on individual body weight. The calculated amount of investigational product (T92 or placebo) will be administrated orally twice daily. Morning dose and evening dose should be administrated at about the same time every day and irrelevant to meals. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05188274
Study type Interventional
Source Tasly Pharmaceuticals, Inc.
Contact Michael H Bloch, MD, PhD
Phone 203-974-7551
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date May 2022
Completion date October 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04114539 - Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension Phase 2
Recruiting NCT04578912 - Transcranial Magnetic Stimulation to Augment Behavior Therapy for Tics N/A
Recruiting NCT04449003 - Influence of Stress and Psychiatric Symptoms on Children With Tourette Syndrome
Recruiting NCT04087616 - Internet-based CBIT for Children With Chronic Tics N/A
Not yet recruiting NCT05184478 - Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? A Pilot Study Phase 1/Phase 2
Recruiting NCT03765463 - Extinction Learning in Youth With Tourette Syndrome N/A
Not yet recruiting NCT04179435 - Cognitive and Brain Development in Adolescents With Gilles de la Tourette Syndrome N/A